The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 26, No. 11, pp. 1400-1408.
© 1992 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, D.
Right arrow Articles by Perry, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, D.
Right arrow Articles by Perry, P.


Research Articles

Nonneuroleptic treatment of disruptive behavior in organic mental syndromes

DA Smith and PJ Perry

OBJECTIVE: To summarize the literature describing nonneuroleptic treatments of unacceptably disruptive behavior in chronically institutionalized psychiatric patients with mental retardation, autism, organic brain syndrome, and dementia. DATA SOURCES: Relevant articles were identified from a MEDLINE search of the above diagnoses linked with "aggression" and "psychomotor agitation." Additional references were found in the bibliographies of these articles. STUDY SELECTION/DATA EXTRACTION: The studies reviewed were limited to prospective evaluations of nonneuroleptic drug therapy of these behavior disturbances. Case reports, case series, and retrospective studies were excluded. Studies of patients with schizophrenia, affective disorders, and personality disorders were also excluded. DATA SYNTHESIS: Studies of lithium, beta-blockers, carbamazepine, benzodiazepines, and buspirone were adequate for review. As a rule, these studies are hampered by poor design. The lithium studies suggest that mentally retarded patients with behavior disturbances may respond to lithium treatment. The beta-blocker studies suggest improvement in patients with mental retardation, autism, organic brain syndrome, and dementia. Neuroleptic discontinuation or a decrease in dose was possible in some patients. The carbamazepine studies were inconclusive. Carbamazepine should be reserved for patients with concomitant seizure disorders. Benzodiazepines were helpful in treating elderly demented patients. Thus far, buspirone has been evaluated in only a few, poorly designed studies and is not yet recommended for treatment of behavior disturbances. CONCLUSIONS: Legislation has restricted the use of neuroleptics in many patients receiving long-term healthcare. Despite the questionable validity of the studies reviewed, lithium, beta-blockers, carbamazepine, and benzodiazepines may be considered as alternatives to neuroleptics in selected cases.


This article has been cited by other articles:


Home page
Adv. Psychiatr. Treat.Home page
S. L. Einfeld
Systematic management approach to pharmacotherapy for people with learning disabilities
Adv. Psychiatr. Treat., January 1, 2001; 7(1): 43 - 49.
[Full Text]


Home page
Clin Child Psychol PsychiatryHome page
D. Dossetor
The Hit and Miss of Magic Bullets: A Guide to Psychotropic Medication for Young People with Intellectual Handicap
Clinical Child Psychology and Psychiatry, January 1, 1997; 2(1): 65 - 93.
[Abstract]


Home page
Journal of Pharmacy PracticeHome page
C. F. Caley
The Pharmacotherapy of Human Aggression: A Review
Journal of Pharmacy Practice, April 1, 1996; 9(2): 133 - 143.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1992 by Harvey Whitney Books Company.